Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other financing activities (2016 - 2023)

Historic Other financing activities for Viking Therapeutics (VKTX) over the last 8 years, with Q1 2023 value amounting to $37000.0.

  • Viking Therapeutics' Other financing activities changed N/A to $37000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $56000.0, marking a year-over-year change of. This contributed to the annual value of $22000.0 for FY2022, which is 5217.39% down from last year.
  • According to the latest figures from Q1 2023, Viking Therapeutics' Other financing activities is $37000.0.
  • Viking Therapeutics' 5-year Other financing activities high stood at $37000.0 for Q1 2023, and its period low was $7000.0 during Q4 2019.
  • In the last 3 years, Viking Therapeutics' Other financing activities had a median value of $19000.0 in 2021 and averaged $21000.0.
  • Over the last 5 years, Viking Therapeutics' Other financing activities had its largest YoY gain of 9752.65% in 2019, and its largest YoY loss of 9752.65% in 2019.
  • Viking Therapeutics' Other financing activities (Quarter) stood at $7000.0 in 2019, then soared by 171.43% to $19000.0 in 2021, then skyrocketed by 94.74% to $37000.0 in 2023.
  • Its Other financing activities stands at $37000.0 for Q1 2023, versus $19000.0 for Q4 2021 and $7000.0 for Q4 2019.